Impact of HIV genotyping and drug levels on the respons... [AIDS. 2002] - PubMed

Save items

loading

Related citations in PubMed

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens. [Ther Drug Monit. 2001]
Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.
Pellegrin I, Breilh D, Birac V, Deneyrolles M, Mercié P, Trylesinski A, Neau D, Saux MC, Fleury HJ, Pellegrin JL. Ther Drug Monit. 2001 Aug; 23(4):332-40.
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir. [J Acquir Immune Defic Syndr. 2...]
The pharmacokinetics, safety, and initial virologic response of a triple-protease inhibitor salvage regimen containing amprenavir, saquinavir, and ritonavir.
Corbett AH, Eron JJ, Fiscus SA, Rezk NL, Kashuba AD. J Acquir Immune Defic Syndr. 2004 Aug 1; 36(4):921-8.
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients. [Antiviral Res. 2000]
The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
Karmochkine M, Si Mohamed A, Piketty C, Ginsburg C, Raguin G, Schneider-Fauveau V, Gutmann L, Kazatchkine MD, Belec L. Antiviral Res. 2000 Sep; 47(3):179-88.
Review Saquinavir: a review of its use in boosted regimens for treating HIV infection. [Drugs. 2003]
Review Saquinavir: a review of its use in boosted regimens for treating HIV infection.
Plosker GL, Scott LJ. Drugs. 2003; 63(12):1299-324.
Review HIV-1 protease inhibitors. [AIDS Clin Rev. 1997]
Review HIV-1 protease inhibitors.
Deeks SG, Volberding PA. AIDS Clin Rev. 1997-1998; :145-85.

See reviews... See all...

Cited by 2 PubMed Central articles

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients. [Eur J Med Res. 2010]
Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.
Stephan C, Jaeger H, Carganico A, Knecht G, Lutz T, Mayr C, Mosthaf FA, Koeppe S, Mueller M, Wolf E, et al. Eur J Med Res. 2010 Sep 24; 15(9):369-76.
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients. [Antimicrob Agents Chemother. 2...]
Clinical and pharmacokinetic data support once-daily low-dose boosted saquinavir (1,200 milligrams saquinavir with 100 milligrams ritonavir) in treatment-naive or limited protease inhibitor-experienced human immunodeficiency virus-infected patients.
Marin-Niebla A, Lopez-Cortes LF, Ruiz-Valderas R, Viciana P, Mata R, Gutierrez A, Pascual R, Rodriguez M. Antimicrob Agents Chemother. 2007 Jun; 51(6):2035-42. Epub 2007 Mar 19.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.
Cited in Books
NCBI Bookshelf books that cite the current articles.

Recent activity

Clear Turn Off Turn On

Impact of HIV genotyping and drug levels on the response to salvage therapy with...
Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.
AIDS. 2002 Sep 27 ;16(14):1964-6.

PubMed
Crystallization, X-ray characterization and selenomethionine phasing of Mlc1p bo...
Crystallization, X-ray characterization and selenomethionine phasing of Mlc1p bound to IQ motifs from myosin V.
Acta Crystallogr D Biol Crystallogr. 2002 Oct ;58(Pt 10 Pt 2):1882-5. Epub 2002 Sep 28 .

PubMed
Rowe and Kahn's model of successful aging revisited: positive spirituality--the ...
Rowe and Kahn's model of successful aging revisited: positive spirituality--the forgotten factor.
Gerontologist. 2002 Oct ;42(5):613-20.

PubMed
Neuroscience. Drug find could give ravers the jitters.
Neuroscience. Drug find could give ravers the jitters.
Science. 2002 Sep 27 ;297(5590):2185-7.

PubMed
Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamin...
Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptors.
J Neurosci. 2002 Oct 1 ;22(19):8705-10.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.

Source

MeSH Terms, Substances

MeSH Terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 2 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information